Estrella Immunopharma, Inc.
ESLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $43 | $35 | $34 | $44 |
| - Cash | $2 | $1 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $41 | $33 | $33 | $43 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$5 | -$6 | -$2 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$5 | -$6 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.15 | -0.058 | -0.029 |
| % Growth | 13.3% | -157.7% | -103.5% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$1 |